Aurinia Pharmaceuticals

Historical price data

Aurinia Pharmaceuticals is a Canadian biotech company with a mission to deliver transformative therapies for autoimmune diseases. Its core achievement is the successful FDA approval and commercialization of LUPKYNIS, a first-in-class oral treatment for lupus nephritis. The company's strategy is to maximize the global potential of LUPKYNIS while leveraging its expertise to develop a pipeline of novel candidates, including a dual BAFF/APRIL inhibitor, to build a sustainable, multi-product autoimmune franchise.

Next-generation calcineurin inhibitor optimization and dual BAFF/APRIL pathway inhibition for autoimmune diseases.

LUPKYNIS competes with standard-of-care immunosuppressants (mycophenolate), the biologic belimumab, and off-label use of tacrolimus in lupus nephritis. The broader pipeline will eventually face competition from established and emerging biologic therapies across various autoimmune indications.